Resolution of Remodeling in Eosinophilic Esophagitis Correlates with Epithelial Response to Topical Corticosteroids

Overview

Journal Allergy

Specialty Allergy & Immunology

Date 2009 Oct 3

PMID 19796194

Citations 123

Authors

S S Aceves

R O Newbury

D Chen

J Mueller

R Dohil

H Hoffman

J F Bastian

D H Broide

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal remodeling occurs in eosinophilic esophagitis (EE) patients but whether the components of remodeling in the subepithelium are reversible by administration of topical oral corticosteroids is unknown.

Methods: We quantitated the degree of lamina propria remodeling in esophageal biopsies obtained before and after at least 3 months of therapy with budesonide in 16 pediatric EE subjects. In addition, we investigated whether corticosteroid therapy modulated vascular activation (expression of VCAM-1; level of interstitial edema), TGFbeta(1) activation (levels of TGFbeta(1), phosphorylated Smad2/3), and performed a pilot analysis of a polymorphism in the TGFbeta(1) promoter in relation to EE subjects who had reduced remodeling with budesonide therapy.

Results: EE subjects were stratified based on the presence (n = 9) or absence (n = 7) of decreased epithelial eosinophilia following budesonide. Patients with residual eosinophil counts of <or=7 eosinophils per high power field in the epithelial space (responders) demonstrated significantly reduced esophageal remodeling with decreased fibrosis, TGFbeta(1) and pSmad2/3 positive cells, and decreased vascular activation in association with budesonide therapy. Responders were more likely to have a CC genotype at the -509 position in the TGFbeta(1) promoter.

Conclusions: Reductions in epithelial eosinophils following budesonide therapy were associated with significantly reduced esophageal remodeling.

Citing Articles

Role of the TGF-β cytokine and its gene polymorphisms in asthma etiopathogenesis.

Plichta J, Panek M Front Allergy. 2025; 6:1529071.

PMID: 39949968 PMC: 11821632. DOI: 10.3389/falgy.2025.1529071.

A Canadian multicenter pediatric eosinophilic esophagitis cohort: Evidence for a nondilation approach to esophageal narrowing.

Burnett D, Avinashi V, Hoang T, Otley A, Persad R, Sherlock M JPGN Rep. 2025; 6(1):19-26.

PMID: 39944104 PMC: 11810807. DOI: 10.1002/jpr3.12149.

Amphiregulin-producing T2 cells facilitate esophageal fibrosis of eosinophilic esophagitis.

Kaneko T, Iwamura C, Kiuchi M, Kurosugi A, Onoue M, Matsumura T J Allergy Clin Immunol Glob. 2024; 3(3):100287.

PMID: 39040657 PMC: 11260569. DOI: 10.1016/j.jacig.2024.100287.

Esophageal remodeling in eosinophilic esophagitis.

Shaker A Curr Opin Gastroenterol. 2024; 40(4):291-298.

PMID: 38661722 PMC: 11156539. DOI: 10.1097/MOG.0000000000001031.

A Multicenter Long-Term Cohort Study of Eosinophilic Esophagitis Variants and Their Progression to Eosinophilic Esophagitis Over Time.

Greuter T, Straumann A, Fernandez-Marrero Y, Germic N, Hosseini A, Chanwangpong A Clin Transl Gastroenterol. 2024; 15(4):e00664.

PMID: 38318864 PMC: 11042771. DOI: 10.14309/ctg.0000000000000664.

References

Kapel R, Miller J, Torres C, Aksoy S, Lash R, Katzka D . Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology. 2008; 134(5):1316-21. DOI: 10.1053/j.gastro.2008.02.016. View

Chehade M, Sampson H, Morotti R, Magid M . Esophageal subepithelial fibrosis in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2007; 45(3):319-28. DOI: 10.1097/MPG.0b013e31806ab384. View

Mishra A, Wang M, Pemmaraju V, Collins M, Fulkerson P, Abonia J . Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology. 2008; 134(1):204-14. PMC: 2654267. DOI: 10.1053/j.gastro.2007.10.002. View

Konikoff M, Noel R, Blanchard C, Kirby C, Jameson S, Buckmeier B . A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology. 2006; 131(5):1381-91. DOI: 10.1053/j.gastro.2006.08.033. View

Straumann A, Spichtin H, Grize L, Bucher K, Beglinger C, Simon H . Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2004; 125(6):1660-9. DOI: 10.1053/j.gastro.2003.09.024. View

Furuta G, Liacouras C, Collins M, Gupta S, Justinich C, Putnam P . Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007; 133(4):1342-63. DOI: 10.1053/j.gastro.2007.08.017. View

Silverman E, Palmer L, Subramaniam V, Hallock A, Mathew S, Vallone J . Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med. 2003; 169(2):214-9. DOI: 10.1164/rccm.200307-973OC. View

Broide D . Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol. 2008; 121(3):560-70. PMC: 2386668. DOI: 10.1016/j.jaci.2008.01.031. View

Schaefer E, Fitzgerald J, Molleston J, Croffie J, Pfefferkorn M, Corkins M . Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol. 2008; 6(2):165-73. DOI: 10.1016/j.cgh.2007.11.008. View

10.

Loke T, Mallett K, Ratoff J, OConnor B, Ying S, Meng Q . Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol. 2006; 118(2):368-75. DOI: 10.1016/j.jaci.2006.04.055. View

11.

Salah Khalil M, El Nahas A, Blakemore A . Transforming growth factor-beta1 SNPs: genetic and phenotypic correlations in progressive kidney insufficiency. Nephron Exp Nephrol. 2005; 101(2):e31-41. DOI: 10.1159/000086227. View

12.

Ravelli A, Villanacci V, Ruzzenenti N, Grigolato P, Tobanelli P, Klersy C . Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr. 2006; 42(5):510-5. DOI: 10.1097/01.mpg.0000215312.78664.b9. View

13.

Aceves S, Newbury R, Dohil R, Bastian J, Broide D . Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2007; 119(1):206-12. DOI: 10.1016/j.jaci.2006.10.016. View

14.

Ueda T, Niimi A, Matsumoto H, Takemura M, Yamaguchi M, Matsuoka H . TGFB1 promoter polymorphism C-509T and pathophysiology of asthma. J Allergy Clin Immunol. 2007; 121(3):659-64. DOI: 10.1016/j.jaci.2007.10.005. View

15.

Vanderheyden A, Petras R, DeYoung B, Mitros F . Emerging eosinophilic (allergic) esophagitis: increased incidence or increased recognition?. Arch Pathol Lab Med. 2007; 131(5):777-9. DOI: 10.5858/2007-131-777-EEAEII. View

16.

Aceves S, Newbury R, Dohil R, Schwimmer J, Bastian J . Distinguishing eosinophilic esophagitis in pediatric patients: clinical, endoscopic, and histologic features of an emerging disorder. J Clin Gastroenterol. 2007; 41(3):252-6. DOI: 10.1097/01.mcg.0000212639.52359.f1. View

17.

Aceves S, Bastian J, Newbury R, Dohil R . Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol. 2007; 102(10):2271-9. DOI: 10.1111/j.1572-0241.2007.01379.x. View